Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Update on key adverse events

Keyphrases

• Adverse Events 100%
• Chronic Myeloid Leukemia 100%
• Tyrosine Kinase Inhibitor Therapy 100%
• Tyrosine Kinase Inhibitor 60%
• Clinical Trials 40%
• Patient Outcomes 20%
• Current Treatment 20%
• Clinical Benefit 20%
• Treatment Recommendations 20%
• Clinical Potential 20%
• Potential Risk 20%
• Appropriate Therapy 20%
• Adverse Event Management 20%
• Risk-benefit 20%
• Adherence to Therapy 20%
• BCR-ABL1 20%

Medicine and Dentistry

• Adverse Event 100%
• Chronic Myelogenous Leukemia 100%
• Tyrosine-Kinase Inhibitor 100%
• Clinical Trial 40%
• Patient Compliance 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Clinical Trial 40%